Company: ROTH Capital Partners
Job title: MD & Senior Research Analyst, Co-Head of Biotechnology Research
Yasmeen has been a Senior Research Analyst at ROTH since 2017, covering companies that are developing therapeutics to treat various liver diseases and conditions, including Nonalcoholic Steatohepatitis (NASH). She also covers companies that are developing products aligned in the orphan and ultra-orphan therapeutics, as well as women’s health.
Dr. Rahimi has extensive expertise in NASH and liver metabolism with 16 publications in highly prestigious journals. She trained at Yale University in the laboratory of Dr. Gerald Shulman, a world-renowned endocrinologist who pioneered the understanding of lipid-induced insulin resistance. In addition, she completed her Ph.D. training in the laboratory of Dr. Robert A. Harris, a distinguished biochemist at Indiana University.